At what enterprise value was PHARMACORD acquired in 2024?

You can find the full valuation details of PHARMACORD on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of PHARMACORD when it was acquired by PERMIRA?

The exact EV/EBITDA multiple for PHARMACORD is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was PHARMACORD acquired by PERMIRA?

PHARMACORD was acquired by PERMIRA in 2024.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the PHARMACORD acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the PHARMACORD deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.permira.com/news-and-insights/announcements/permira-announces-substantial-investment-in-pharmacord

← DATABASE

Home Database Healthcare & PharmaPHARMACORD

06/2024

PHARMACORD acquired by PERMIRA

UNITED STATES Healthcare Services / Health Tech REV 1m USD - 100m USD

Context

PharmaCord has been acquired by a company backed by Permira following a definitive agreement signed in June 2024. The transaction introduces new capital to PharmaCord while the existing management team, led by founder and CEO Nitin Sahney, retains operational control and a significant equity position. The investment is subject to customary regulatory approvals and is anticipated to close in the fourth quarter of 2024. Financial advisers to PharmaCord were Centerview Partners, with legal counsel provided by Willkie Farr & Gallagher; Permira’s advisers included Jefferies LLC and Leerink Partners, and its legal counsel was Skadden, Arps, Slate, Meagher & Flom LLP. Permira’s participation aligns with its strategy to expand in technology‑enabled healthcare services that support specialty pharmaceuticals. The firm identifies increasing therapeutic complexity and heightened demand for patient‑centric solutions as drivers of market opportunity, and views PharmaCord’s digital platform and extensive client relationships as complementary to its existing portfolio. By providing growth capital and leveraging its operational expertise, Permira aims to accelerate product development, broaden service offerings, and extend the company’s reach into additional therapeutic categories and geographic regions. Post‑closing, PharmaCord is expected to integrate additional technology resources, scale its analytics capabilities, and increase the volume of supported drug products. The partnership is projected to enhance operational efficiency through shared best practices and enable faster onboarding of new pharmaceutical clients. Expanded capital may also fund recruitment of specialized talent and the development of new adherence‑tracking tools, thereby strengthening the company’s position as a commercialization partner in the specialty drug market. The combined effort is anticipated to generate incremental revenue growth and improve patient outcome metrics across the serviced therapies.

PHARMACORD, which reported an EBITDA margin of LOGIN in 2024, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

PharmaCord LLC is a United States‑based provider of patient services for the pharmaceutical industry. Established in 2015, the company designs and operates technology‑enabled programs that guide patients through the specialty medication journey. Its portfolio includes awareness campaigns, insurance navigation, co‑pay assistance, and adherence monitoring delivered via proprietary digital platforms and call‑center operations. The firm partners with more than 30 pharmaceutical manufacturers and supports over 100 distinct drug products across therapeutic areas such as oncology, rare diseases, and immunology. Revenue is generated through service contracts that combine fixed fees with performance‑based components linked to patient enrollment and outcome metrics. PharmaCord’s client base spans large multinational drugmakers, mid‑size biotech firms, and specialty pharmacy networks, each requiring compliance with regulatory standards in the United States and selected international markets.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (USD)

Year

Rev

EBITDA

EBIT

2024

2023

Similar deals in Healthcare & Pharma

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
04/2025	TRANSCARENT	ACCOLADE	UNITED STATES	Healthcare Services	Transcarent completed its acquisition of Accolade on April 8, 2025, following a definitive agreement announced on January 8, 2025. The transaction is structured as a full‑takeover, with Accolade ceasing to be a Nasdaq‑listed company and becoming a privately held subsidiary within the combined group
07/2024	ARDIAN	MASCO GROUP	ITALY	Healthcare Services	Ardian acquired a majority stake in Masco Group from RSBG Infrastructure (the investment arm of the RAG-Stiftung). The transaction marks a new phase of international expansion for Masco, which has grown significantly through acquisitions such as Stilmas, Olsa, and BCD Engineering
05/2024	21 INVEST / OAKLEY CAPITAL INVESTMENTS	PRODUCT LIFE	FRANCE	Healthcare Services	21 Invest France acquired a majority stake in ProductLife Group from its founder who sought to institutionalize the company and secure resources for its next growth phase. The transaction was structured to allow the management team to reinvest significantly alongside 21 Invest
10/2023	MOTION EQUITY PARTNERS	BANOOK	FRANCE	Healthcare Services	Motion Equity Partners acquired a majority stake in Banook Group from Turenne Sante. The transaction was structured as a growth-oriented LBO, with the management team and Turenne Sante reinvesting substantially
09/2023	PERMIRA	ERGOMED	UNITED KINGDOM	Healthcare Services	Permira acquired Ergomed in a recommended cash offer, taking the company private from the London Stock Exchange (AIM). The transaction was driven by the thesis that Ergomed's next phase of growth—requiring significant investment in technology and international expansion (particularly in the US)—could be better executed away from the public markets
09/2023	CERBA HEALTHCARE	CIRION BIOPHARMA RESEARCH	CANADA	Healthcare Services	Cerba HealthCare acquired the Canadian CRO Cirion BioPharma Research to integrate it into its global clinical trial business unit, Cerba Research. This move establishes a critical operational hub in North America, allowing the group to offer seamless cross-continental support for drug development programs
06/2023	SUPERNOVA INVEST / HEAL CAPITAL	GLEAMER	FRANCE	Healthcare Services	Gleamer raised €27 million in Series B funding to broaden its AI solution portfolio and accelerate global commercial development. The strategic plan involves expanding the software suite to include CT scans and mammography, aiming to cover 70% of radiologists' daily diagnostic needs
06/2022	ASTORG	OPEN HEALTH	UNITED STATES	Healthcare Services	Astorg has successfully completed the acquisition of OPEN Health from Amulet Capital Partners, executing a significant secondary buyout in the highly attractive healthcare services sector. Through this transaction, Astorg secures a controlling interest in a premier medical affairs and market access business, while the existing management team will continue to helm the organization
11/2020	KERSIA	SOPURA	BELGIUM	Healthcare Services	Kersia acquired 100% of Sopura from its shareholders as part of a strategic build-up program. This transaction was integrated into a larger financing package arranged during the acquirer's own ownership transition to a new private equity sponsor
10/2020	IK PARTNERS	KERSIA	FRANCE	Healthcare Services	IK Investment Partners acquired a majority stake in Kersia from Ardian. This transaction was initiated through exclusive negotiations via the IK IX fund, marking the first deal for this specific vehicle

REFERENCES

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of PHARMACORD by PERMIRA are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Acquirer: permira